Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GELSNASDAQ:OKYONASDAQ:PDSBNASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGELSGelteq$1.71+0.6%$1.49$0.77▼$5.50$16.14MN/A1.01 million shs16,673 shsOKYOOKYO Pharma$1.86-1.1%$1.44$0.81▼$1.98$62.94M-0.27160,318 shs23,406 shsPDSBPDS Biotechnology$1.56-5.5%$1.25$0.85▼$4.42$71.31M1.4573,795 shs395,507 shsPYRGFPyroGenesis Canada$0.37-3.4%$0.33$0.30▼$0.80$69.84M0.7911,105 shs4,073 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGELSGelteq-5.03%+1.80%+1.80%+27.82%+169,999,900.00%OKYOOKYO Pharma+0.53%+1.62%+27.46%+37.23%+30.56%PDSBPDS Biotechnology+7.84%+20.44%+25.95%+23.13%-43.10%PYRGFPyroGenesis Canada+0.05%+14.92%+22.02%+2.22%-5.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGELSGelteqN/AN/AN/AN/AN/AN/AN/AN/AOKYOOKYO Pharma2.1019 of 5 stars3.55.00.00.00.01.70.0PDSBPDS Biotechnology1.782 of 5 stars3.73.00.00.02.10.00.0PYRGFPyroGenesis Canada0.3107 of 5 stars0.02.00.00.01.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGELSGelteq 0.00N/AN/AN/AOKYOOKYO Pharma 3.00Buy$7.00276.34% UpsidePDSBPDS Biotechnology 3.33Buy$9.00476.92% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GELS, PDSB, OKYO, and PYRGF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/27/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $13.003/13/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.003/7/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGELSGelteqN/AN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/APDSBPDS BiotechnologyN/AN/AN/AN/A$0.84 per shareN/APYRGFPyroGenesis Canada$9.14M7.64N/AN/A($0.01) per share-37.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGELSGelteqN/AN/A0.00∞N/AN/AN/AN/AN/AOKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/AN/APDSBPDS Biotechnology-$42.94M-$0.94N/AN/AN/AN/A-139.57%-67.22%8/12/2025 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.02N/A∞N/A-115.14%N/A-60.81%N/ALatest GELS, PDSB, OKYO, and PYRGF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A3/27/2025Q4 2024PDSBPDS Biotechnology-$0.29-$0.21+$0.08-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGELSGelteqN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGELSGelteqN/AN/AN/AOKYOOKYO PharmaN/A0.28N/APDSBPDS Biotechnology0.552.842.84PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGELSGelteqN/AOKYOOKYO Pharma2.97%PDSBPDS Biotechnology26.84%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipGELSGelteqN/AOKYOOKYO Pharma40.46%PDSBPDS Biotechnology9.20%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGELSGelteqN/A9.44 millionN/AN/AOKYOOKYO Pharma733.84 million20.15 millionNot OptionablePDSBPDS Biotechnology2045.71 million33.86 millionOptionablePYRGFPyroGenesis Canada90186.69 million96.34 millionNo DataGELS, PDSB, OKYO, and PYRGF HeadlinesRecent News About These CompaniesPyroGenesis Canada (NASDAQ:PYRGF) Trading Up 1.1% - What's Next?June 1, 2025 | marketbeat.comHigh-Tech Micro Cap Rallies After Securing Boeing Supplier StatusMay 29, 2025 | msn.comPyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica SamplesMay 28, 2025 | globenewswire.comPyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent AnalysisMay 21, 2025 | globenewswire.comPyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant BaghouseMay 15, 2025 | globenewswire.comPyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comPyroGenesis Announces First Quarter 2025 ResultsMay 13, 2025 | globenewswire.comPyroGenesis Provides Update on Fumed Silica ProjectMay 13, 2025 | globenewswire.comPyroGenesis Closes $2,385,000 First Tranche in Previously Announced LoanMay 12, 2025 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Trading Down 0.2% - Should You Sell?May 11, 2025 | marketbeat.comPyroGenesis Schedules First Quarter 2025 Financial Results and Business Update Conference CallMay 9, 2025 | globenewswire.comPyroGenesis Announces Closing of Non-Brokered Private Placement of up to $5,750,000May 5, 2025 | globenewswire.comP. Peter Pascali Updates Early Warning ReportApril 10, 2025 | globenewswire.comPyroGenesis Inc. (PYRGF) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comPyroGenesis Announces Fourth Quarter and Full Year 2024 ResultsMarch 31, 2025 | globenewswire.comPyroGenesis Schedules 2024 Fiscal Year Financial Results and Business Update Conference CallMarch 26, 2025 | globenewswire.comPyroGenesis Inc.: PyroGenesis Provides Update on Varennes Carbon Recycling ProjectMarch 21, 2025 | finanznachrichten.dePyroGenesis Provides Update on Varennes Carbon Recycling ProjectMarch 21, 2025 | globenewswire.comHPQ’s Statement on U.S. - Canada Tariff Situation, Reinforces Case for Domestic Fumed Silica ProductionMarch 12, 2025 | markets.businessinsider.comPyroGenesis and GE Vernova Sign Memorandum of Understanding (MOU)March 11, 2025 | globenewswire.comPyroGenesis Provides Response to Impact of U.S. TariffsMarch 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGELS, PDSB, OKYO, and PYRGF Company DescriptionsGelteq NASDAQ:GELS$1.71 +0.01 (+0.59%) As of 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.OKYO Pharma NASDAQ:OKYO$1.86 -0.02 (-1.06%) Closing price 03:59 PM EasternExtended Trading$1.88 +0.02 (+1.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.PDS Biotechnology NASDAQ:PDSB$1.56 -0.09 (-5.45%) Closing price 04:00 PM EasternExtended Trading$1.61 +0.05 (+3.21%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.PyroGenesis Canada NASDAQ:PYRGF$0.37 -0.01 (-3.43%) As of 03:59 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
